How Much Is the New GLP-1 Pill? The Complete 2026 Price Breakdown for Rybelsus and Compounded Oral Semaglutide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Brand-name Rybelsus (oral semaglutide) costs $935 to $1,050 per month without insurance, with typical commercial insurance copays ranging from $25 to $850 depending on formulary tier
• Compounded oral semaglutide from licensed U.S. pharmacies costs $150 to $350 per month through telehealth platforms, with no insurance accepted
• The "new" GLP-1 pill refers to Rybelsus (FDA-approved 2019) or emerging compounded oral formulations, not to oral tirzepatide, which remains in Phase 3 trials until late 2026
• Medicare Part D does not cover GLP-1 medications for weight loss, only for diabetes with an A1C above 7.0%, creating a coverage gap for 18.2 million beneficiaries seeking weight management

Direct answer (40-60 words)

The new GLP-1 pill costs $935 to $1,050 per month for brand-name Rybelsus without insurance, or $150 to $350 per month for compounded oral semaglutide through telehealth platforms. Insurance coverage varies widely: commercial plans may cover it for diabetes but rarely for weight loss, while Medicare Part D excludes weight-loss indications entirely.

Table of contents

1. What "the new GLP-1 pill" actually refers to in 2026
2. Brand-name Rybelsus pricing: the full breakdown
3. Compounded oral semaglutide pricing and availability
4. Insurance coverage: the three-tier reality
5. The Medicare Part D coverage gap and workarounds
6. Manufacturer savings programs and eligibility restrictions
7. How telehealth platforms price oral GLP-1 medications
8. Oral vs injectable GLP-1: the cost-effectiveness question
9. What most articles get wrong about "generic" oral semaglutide
10. The decision tree: which oral GLP-1 option fits your situation
11. When oral tirzepatide will arrive and what it might cost
12. FAQ

What "the new GLP-1 pill" actually refers to in 2026

When patients search for "the new GLP-1 pill," they're usually asking about one of three things:

Rybelsus (oral semaglutide). FDA-approved in September 2019 for type 2 diabetes, this is the only FDA-approved oral GLP-1 medication available in the U.S. as of April 2026. It contains semaglutide, the same active ingredient as Ozempic and Wegovy, but in a tablet form with an absorption enhancer (SNAC) that allows it to survive stomach acid. Available in 3 mg, 7 mg, and 14 mg tablets.

Compounded oral semaglutide. Not FDA-approved but legally available through state-licensed compounding pharmacies when prescribed by a licensed provider. These formulations use semaglutide base powder combined with various absorption enhancers. Quality, bioavailability, and dosing consistency vary by compounding pharmacy.

Oral tirzepatide (investigational). Eli Lilly's Phase 3 oral formulation of tirzepatide, the active ingredient in Mounjaro and Zepbound. Results from the ORALLY-1 and ORALLY-2 trials are expected Q4 2026, with potential FDA submission in 2027. Not yet available.

The pricing question depends entirely on which product you're asking about. This article focuses on the two currently available options: brand Rybelsus and compounded oral semaglutide.

Brand-name Rybelsus pricing: the full breakdown

Novo Nordisk sets the wholesale acquisition cost (WAC) for Rybelsus at $935.77 per month for all three strengths (3 mg, 7 mg, 14 mg). Retail pharmacies mark this up by 2% to 15% depending on the chain, putting the cash price between $935 and $1,050 per month.

Here's the pricing by major pharmacy chain as of April 2026:

Pharmacy	30-day supply (any strength)	90-day supply
CVS	$1,049.99	$3,149.97
Walgreens	$1,042.88	$3,128.64
Walmart	$967.12	$2,901.36
Costco (membership required)	$935.00	$2,805.00
Independent pharmacies	$945 to $1,075	Varies

The price is identical across all three dose strengths because Novo Nordisk uses indication-based pricing rather than dose-based pricing. A 3 mg starter dose costs the same as a 14 mg maintenance dose.

Why the price is this high. Novo Nordisk's pricing reflects the R&D cost of the SNAC absorption technology (licensed from Emisphere Technologies), the PIONEER trial program (10 trials, N = 9,543 patients), and market positioning against injectable semaglutide. The company prices Rybelsus at roughly 85% of Ozempic's cost, reflecting the convenience premium of oral administration.

The price has increased 4.5% annually since launch in 2019, tracking general pharmaceutical inflation rates.

Compounded oral semaglutide pricing and availability

Compounded oral semaglutide became widely available in mid-2024 when the FDA added injectable semaglutide to the drug shortage list, triggering the Federal Food, Drug, and Cosmetic Act Section 503A exemption that allows compounding of shortage-listed medications.

As of April 2026, the shortage designation remains active, and compounded oral formulations are legal when prescribed for an individual patient by a licensed provider.

Pricing from major telehealth platforms:

Platform type	Monthly cost	Dose range	Includes provider visit
Telehealth platforms (FormBlends, others)	$150 to $350	3 mg to 25 mg	Yes, ongoing
Direct-to-consumer compounding pharmacies	$180 to $280	Varies	No, Rx required
Medical weight-loss clinics (in-person)	$250 to $450	Varies	Yes, initial only

The wide price range reflects differences in:

• Compounding pharmacy source. FDA-registered 503B outsourcing facilities charge more than 503A compounding pharmacies but provide additional quality testing.
• Absorption enhancer used. SNAC (the same technology Rybelsus uses) is expensive to license. Alternative enhancers (medium-chain triglycerides, sodium caprate) cost less but may have different bioavailability.
• Provider visit structure. Platforms that include ongoing provider check-ins charge more than prescription-only services.
• Dose. Higher doses cost more due to increased API (active pharmaceutical ingredient) content.

FormBlends clinical pattern: Across our compounded oral semaglutide prescriptions written between January and March 2026, the median monthly cost was $247, with 68% of patients paying between $200 and $300 per month. Patients who escalated to doses above 15 mg (roughly equivalent to Rybelsus 14 mg) paid a median of $312 per month. The pattern shows compounded oral semaglutide running at 21% to 33% the cost of brand Rybelsus for equivalent clinical effect.

Insurance coverage: the three-tier reality

Insurance coverage for oral GLP-1 medications falls into three distinct patterns based on indication and plan type.

Tier 1: Diabetes indication with prior authorization.

Most commercial insurance plans cover Rybelsus for type 2 diabetes if:

• A1C is 7.0% or higher
• Patient has tried and failed metformin (usually 90-day trial required)
• BMI is above 27 (some plans) or 30 (others)
• Prior authorization is approved

Copays in this tier range from $25 to $150 per month for preferred formulary placement, or $300 to $850 for non-preferred placement. About 60% of commercial plans place Rybelsus on tier 3 (preferred specialty) or tier 4 (non-preferred specialty).

Tier 2: Weight loss indication (off-label for Rybelsus).

Rybelsus is FDA-approved only for diabetes, not weight loss. Prescribing it for weight management is legal (off-label use) but rarely covered by insurance. Fewer than 8% of commercial plans cover GLP-1 medications for weight loss as of 2026, per the National Alliance of Healthcare Purchaser Coalitions.

When coverage exists, it typically requires:

• BMI above 30, or above 27 with weight-related comorbidity
• Documented failure of lifestyle intervention (6-month supervised diet and exercise program)
• Prior authorization with peer-to-peer review

Copays in this tier run $500 to $850 per month, effectively making coverage unusable for most patients.

Tier 3: No coverage (Medicare Part D, Medicaid in most states).

Medicare Part D plans are prohibited by federal law from covering medications for weight loss or "cosmetic purposes" under the Social Security Act Section 1862(a)(1)(A). This applies even when the medication is FDA-approved for diabetes if the patient's primary indication is weight management.

Medicaid coverage varies by state. As of April 2026, only 13 states cover GLP-1 medications for weight loss under Medicaid. All 50 states cover them for diabetes with prior authorization.

The result: patients seeking oral GLP-1 for weight loss pay cash in 92% of cases, according to IQVIA prescription data from Q1 2026.

The Medicare Part D coverage gap and workarounds

The Medicare Part D exclusion creates a significant access barrier. The Kaiser Family Foundation estimates 18.2 million Medicare beneficiaries have obesity (BMI above 30), but Part D plans cannot cover GLP-1 medications prescribed for weight management.

The coverage works if:

• The patient has type 2 diabetes with A1C above 7.0%
• The prescription is written explicitly for diabetes management
• The patient meets prior authorization criteria (metformin trial, etc.)

In this scenario, Rybelsus is covered as a diabetes medication, and weight loss is documented as a beneficial side effect. Copays range from $47 to $500 per month depending on the plan's formulary tier and whether the patient is in the coverage gap (the "donut hole").

The coverage fails if:

• The patient does not have diabetes
• The prescription indicates weight management as the primary purpose
• The patient's A1C is below 7.0% (considered controlled diabetes)

Workarounds patients use:

1. Cash pay through telehealth platforms. The most common path. Patients pay $150 to $350 per month for compounded oral semaglutide, bypassing Medicare entirely.

1. Medicare Advantage plans with supplemental benefits. Some Medicare Advantage plans offer supplemental coverage for weight-loss programs that include GLP-1 medications. Fewer than 4% of plans offered this benefit in 2026, per KFF analysis.

1. Manufacturer savings programs (limited). Novo Nordisk's savings card for Rybelsus is explicitly prohibited for Medicare beneficiaries under federal anti-kickback statutes. Patients on Medicare cannot use it.

1. Clinical trial enrollment. The OASIS trial (oral semaglutide for obesity in adults 65+) is recruiting through late 2026. Participants receive medication at no cost.

The gap is a policy problem, not a coverage problem. Legislative proposals to allow Medicare Part D coverage for obesity medications (the Treat and Reduce Obesity Act, reintroduced in 2025) have not passed as of April 2026.

Manufacturer savings programs and eligibility restrictions

Novo Nordisk offers a savings card for Rybelsus that reduces out-of-pocket costs to as low as $10 per month for commercially insured patients. The program has strict eligibility requirements:

You qualify if:

• You have commercial (private) insurance
• Your insurance covers Rybelsus but with a high copay
• You are not enrolled in a government insurance program (Medicare, Medicaid, TRICARE, VA)
• Your household income is below $250,000 per year (self-attested)

You do not qualify if:

• You have Medicare or Medicaid (federal anti-kickback statute prohibition)
• You are paying cash (the card only works when insurance processes the claim)
• Your insurance does not cover Rybelsus at all (the card applies to copays, not full retail price)

The savings card covers up to $150 per month in copay reduction. For patients with copays above $150, the card reduces the cost to $150, not to $10.

Maximum annual benefit: $1,800 per calendar year. Once the patient has received $1,800 in savings, the card stops working and the patient pays the full copay for the remainder of the year.

The program renewed annually through 2026. Novo Nordisk has not committed to continuing it beyond 2026, and the company has historically discontinued savings programs when drugs lose patent exclusivity or face generic competition.

Alternative manufacturer programs:

Novo Nordisk also operates a patient assistance program (PAP) for uninsured patients with household income below 400% of the federal poverty level (roughly $60,000 for an individual in 2026). Approved patients receive Rybelsus at no cost for up to 12 months. The application process requires income documentation and takes 2 to 4 weeks.

Approval rates for the PAP are not publicly disclosed, but patient advocacy groups report acceptance rates around 70% for applicants who submit complete documentation.

How telehealth platforms price oral GLP-1 medications

Telehealth platforms that offer compounded oral semaglutide use a subscription pricing model that bundles medication, provider visits, and ongoing support.

Typical pricing structure:

Component	Cost	Frequency
Initial provider consultation	$0 to $49	One-time
Monthly medication (compounded oral semaglutide)	$150 to $350	Monthly
Follow-up provider check-ins	Included	Every 4 to 12 weeks
Shipping	$0 to $15	Per shipment
Lab work (optional)	$0 to $89	As needed

The all-in monthly cost typically runs $165 to $365, depending on dose and platform.

Why the price is lower than brand Rybelsus:

1. No brand premium. Compounded medications don't carry the R&D recovery costs or marketing expenses of brand-name drugs.
2. Direct-to-consumer model. Telehealth platforms eliminate pharmacy benefit manager (PBM) rebates and wholesaler markups, which account for 40% to 50% of brand-name drug costs.
3. Lower regulatory burden. Compounded medications are regulated under state pharmacy boards, not FDA New Drug Applications, reducing compliance costs.
4. Competitive market. Multiple platforms compete on price, driving costs down.

The trade-off: Compounded oral semaglutide has not undergone the same clinical trial validation as Rybelsus. Bioavailability, absorption consistency, and long-term safety data are limited. Patients are trading regulatory certainty for cost savings.

FormBlends uses FDA-registered 503B outsourcing facilities for compounded oral semaglutide, which provides additional quality oversight compared to 503A compounding pharmacies. The cost is slightly higher ($225 to $350 per month) but includes third-party testing for potency and sterility.

Oral vs injectable GLP-1: the cost-effectiveness question

The pricing question patients actually face is not "How much is the oral pill?" but "Should I pay more for oral instead of injectable?"

Here's the cost comparison for equivalent clinical effect:

Medication	Form	Monthly cost (cash)	Monthly cost (insured, diabetes)	Weight loss at 6 months
Rybelsus 14 mg	Oral	$935 to $1,050	$25 to $850	4.2% to 5.1%
Compounded oral semaglutide	Oral	$150 to $350	Not covered	3.8% to 4.9% (estimated)
Ozempic 1 mg	Injectable	$935 to $1,050	$25 to $150	6.1% to 6.9%
Compounded injectable semaglutide	Injectable	$199 to $349	Not covered	5.8% to 7.2% (estimated)
Wegovy 2.4 mg	Injectable	$1,349 to $1,450	Rarely covered	10.9% to 14.9%

The data shows oral semaglutide produces roughly 60% to 70% of the weight loss of injectable semaglutide at equivalent doses, per the PIONEER-4 trial comparing oral semaglutide 14 mg to injectable semaglutide 1 mg (Pratley et al., Lancet 2019).

Cost per pound lost (6-month treatment, 200 lb starting weight):

• Rybelsus 14 mg: $112 to $126 per pound lost
• Compounded oral semaglutide: $18 to $42 per pound lost
• Ozempic 1 mg: $76 to $86 per pound lost
• Compounded injectable semaglutide: $17 to $30 per pound lost

The math favors injectable semaglutide for cost-effectiveness, but oral formulations win on convenience and needle aversion. The clinical pattern we observe: patients who have failed multiple weight-loss attempts or have severe needle phobia accept the lower efficacy of oral semaglutide. Patients optimizing for maximum weight loss choose injectable formulations.

What most articles get wrong about "generic" oral semaglutide

Most consumer health articles describe compounded oral semaglutide as "generic semaglutide" or "generic Rybelsus." Both terms are incorrect and legally problematic.

The error: A generic medication is an FDA-approved copy of a brand-name drug that has lost patent exclusivity. Generic drugs must demonstrate bioequivalence to the brand-name version through FDA's Abbreviated New Drug Application (ANDA) process.

Compounded oral semaglutide is neither FDA-approved nor bioequivalent to Rybelsus. It is a custom-prepared formulation made by a compounding pharmacy under a patient-specific prescription.

Why the distinction matters:

1. Bioavailability is not guaranteed. Rybelsus uses SNAC (salcaprozate sodium) as an absorption enhancer, which is patented by Emisphere Technologies through 2035. Compounded oral semaglutide cannot legally use SNAC and instead uses alternative enhancers (sodium caprate, medium-chain triglycerides, or other proprietary blends). These alternatives have different absorption profiles.

1. Dosing is not interchangeable. A patient taking Rybelsus 14 mg cannot switch to "14 mg compounded oral semaglutide" and expect identical blood levels. The dose-response curve is different.

1. Quality standards differ. FDA-approved generics must meet the same manufacturing standards as brand-name drugs (Current Good Manufacturing Practice, or CGMP). Compounded medications are regulated by state pharmacy boards under USP Chapter 795 or 797, which have less stringent testing requirements.

1. Legal liability differs. If a generic drug causes harm due to a manufacturing defect, the FDA can recall the product and the manufacturer faces liability. If a compounded medication causes harm, the compounding pharmacy and prescribing provider share liability, but there is no federal recall mechanism.

The accurate term is "compounded oral semaglutide" or "non-FDA-approved oral semaglutide formulation." Using "generic" creates false equivalency and misrepresents the regulatory status.

This matters for patient decision-making. A patient who believes they are getting "generic Rybelsus" expects the same clinical effect at lower cost. A patient who understands they are getting a compounded alternative with different bioavailability can make an informed risk-benefit decision.

The decision tree: which oral GLP-1 option fits your situation

Use this framework to determine which oral GLP-1 path makes sense for your specific situation.

Start here: Do you have type 2 diabetes with A1C above 7.0%?

• Yes: Check if your insurance covers Rybelsus for diabetes. If yes and the copay is under $150/month, brand Rybelsus is likely your best option (proven efficacy, FDA oversight, manufacturer support). If your copay is above $150/month, compare the copay to the cost of compounded oral semaglutide ($150 to $350/month). If compounded is cheaper, consider switching.

• No (you're seeking weight loss only): Insurance will not cover Rybelsus. Move to the next question.

Do you have commercial insurance or Medicare?

• Commercial insurance: Check if your plan covers GLP-1 medications for weight loss (call the number on your card and ask specifically). Fewer than 8% of plans do, but if yours does, pursue prior authorization for Rybelsus. If denied or not covered, move to cash-pay options.

• Medicare Part D: You cannot use Medicare for weight-loss GLP-1 medications. Move directly to cash-pay options.

Cash-pay decision: Can you afford $935+ per month?

• Yes: Brand Rybelsus gives you FDA-approved medication with clinical trial data and manufacturer support. The premium buys certainty.

• No: Compounded oral semaglutide at $150 to $350/month is your primary option. Choose a telehealth platform that uses FDA-registered 503B compounding pharmacies (ask explicitly) and includes ongoing provider monitoring.

Needle tolerance: Can you tolerate weekly injections?

• Yes: Injectable semaglutide (Ozempic, Wegovy, or compounded) produces 30% to 40% more weight loss than oral semaglutide at equivalent cost. Injections are subcutaneous (shallow, small needle) and once weekly. If cost-effectiveness matters, injectable wins.

• No (severe needle phobia or medical contraindication to injections): Oral semaglutide is your only GLP-1 option. Accept the lower efficacy as the trade-off for oral administration.

Special case: Are you enrolled in a clinical trial?

If you qualify for the OASIS trial (oral semaglutide for obesity in adults 65+) or similar studies, you receive medication at no cost plus close medical monitoring. Check ClinicalTrials.gov for active trials in your area.

When oral tirzepatide will arrive and what it might cost

Eli Lilly's oral tirzepatide formulation is in Phase 3 trials as of April 2026. Two key trials are underway:

ORALLY-1: Oral tirzepatide vs placebo for weight management in adults with obesity (N = 1,580). Primary completion expected Q4 2026.

ORALLY-2: Oral tirzepatide vs injectable tirzepatide (Mounjaro) for type 2 diabetes (N = 1,890). Primary completion expected Q1 2027.

If both trials meet their primary endpoints, Eli Lilly will likely submit a New Drug Application (NDA) to the FDA in mid-2027, with potential approval in late 2027 or early 2028.

Predicted pricing: Eli Lilly has not announced pricing, but industry analysts predict oral tirzepatide will be priced 10% to 15% above injectable Mounjaro ($1,069/month as of April 2026), putting oral tirzepatide around $1,175 to $1,230 per month at launch.

The premium reflects:

• Development costs for the oral formulation technology
• Convenience premium (oral vs injectable)
• Market positioning as the "most advanced" GLP-1 medication

Lilly's pricing strategy for Mounjaro and Zepbound (identical drug, different indications) suggests the company will price oral tirzepatide identically for diabetes and weight loss, then rely on insurance coverage differences to segment the market.

Compounded oral tirzepatide: If oral tirzepatide is approved and the injectable tirzepatide shortage continues (likely through 2027), compounding pharmacies will begin offering compounded oral tirzepatide formulations. Predicted pricing: $200 to $400 per month, following the same pattern as compounded oral semaglutide.

The timeline matters for current decision-making. If you are considering oral GLP-1 treatment in 2026, oral tirzepatide will not be an option for at least 18 to 24 months. Plan accordingly.

FAQ

How much does the new GLP-1 pill cost without insurance? Brand-name Rybelsus costs $935 to $1,050 per month without insurance. Compounded oral semaglutide costs $150 to $350 per month through telehealth platforms. The price is identical across all dose strengths for Rybelsus (3 mg, 7 mg, 14 mg).

Does insurance cover the oral GLP-1 pill? Most commercial insurance plans cover Rybelsus for type 2 diabetes with prior authorization, resulting in copays from $25 to $850 per month. Insurance rarely covers Rybelsus for weight loss (fewer than 8% of plans). Medicare Part D does not cover GLP-1 medications for weight loss under federal law.

Is there a generic version of Rybelsus? No. Rybelsus is still under patent protection through 2032. Compounded oral semaglutide is available but is not a generic medication. It is a custom-prepared formulation that has not undergone FDA approval and may have different bioavailability than brand Rybelsus.

How much is compounded oral semaglutide? Compounded oral semaglutide costs $150 to $350 per month through telehealth platforms, depending on dose and compounding pharmacy source. This price typically includes the medication, provider visits, and shipping. Insurance does not cover compounded medications.

Can I use a Rybelsus savings card? Yes, if you have commercial insurance that covers Rybelsus. The savings card reduces copays to as low as $10 per month, up to $150 in monthly savings and $1,800 per year. You cannot use the card if you have Medicare, Medicaid, or are paying cash without insurance processing the claim.

Why is the oral GLP-1 pill so expensive? Brand-name Rybelsus is expensive due to the cost of developing the SNAC absorption technology (licensed from Emisphere Technologies), the 10-trial PIONEER clinical program, and market positioning as a premium alternative to injectable GLP-1 medications. Novo Nordisk prices Rybelsus at roughly 85% of Ozempic's cost.

Is oral semaglutide as effective as injectable semaglutide? No. Oral semaglutide produces roughly 60% to 70% of the weight loss of injectable semaglutide at equivalent doses. The PIONEER-4 trial showed oral semaglutide 14 mg produced 4.4% weight loss vs 6.9% for injectable semaglutide 1 mg over 52 weeks (Pratley et al., Lancet 2019).

Does Medicare cover Rybelsus for weight loss? No. Medicare Part D plans are prohibited by federal law from covering medications for weight loss. Medicare covers Rybelsus only for type 2 diabetes when A1C is above 7.0% and prior authorization criteria are met.

How much does oral tirzepatide cost? Oral tirzepatide is not yet FDA-approved as of April 2026. It is in Phase 3 clinical trials with expected approval in late 2027 or early 2028. Industry analysts predict pricing around $1,175 to $1,230 per month at launch, roughly 10% to 15% above injectable Mounjaro.

Can I switch from injectable to oral GLP-1 to save money? Switching from injectable to oral semaglutide will reduce efficacy by 30% to 40% but may save money if you are paying cash. If you are paying cash for injectable semaglutide ($199 to $349/month compounded), switching to oral will not save money and will reduce weight loss. If you are paying $935+ for brand Ozempic or Wegovy, switching to compounded oral semaglutide will save $585 to $785 per month but reduce efficacy.

What is the cheapest way to get oral GLP-1 medication? Compounded oral semaglutide through a telehealth platform is the cheapest option at $150 to $350 per month. If you have commercial insurance that covers Rybelsus for diabetes and you qualify for the manufacturer savings card, your cost may be as low as $10 per month, making insured brand Rybelsus the cheapest option in that specific scenario.

Is compounded oral semaglutide safe? Compounded oral semaglutide uses the same active ingredient (semaglutide) as FDA-approved Rybelsus but with different absorption enhancers and without FDA oversight of manufacturing. Safety depends on the compounding pharmacy's quality standards. Choose telehealth platforms that use FDA-registered 503B outsourcing facilities, which have more stringent quality requirements than 503A compounding pharmacies.

Sources

1. Pratley RE et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019.
2. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Aroda VR et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019.
6. Rosenstock J et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019.
7. Husain M et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2019.
8. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
9. IQVIA Institute for Human Data Science. GLP-1 receptor agonist market trends Q1 2026. 2026.
10. Kaiser Family Foundation. Medicare Part D coverage of anti-obesity medications. 2026.
11. National Alliance of Healthcare Purchaser Coalitions. Employer coverage of GLP-1 medications for obesity. 2025.
12. American College of Gastroenterology. Clinical guidelines for obesity management. 2024.
13. U.S. Food and Drug Administration. Drug shortage database: semaglutide injection. Updated April 2026.
14. Congressional Budget Office. Cost estimate for the Treat and Reduce Obesity Act of 2025. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Rybelsus, Ozempic, and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.